Team Science: The SU2C Dream Team Initiative
|
|
- Sylvia Gallagher
- 5 years ago
- Views:
Transcription
1 Team Science: The SU2C Dream Team Initiative Pat J. Morin, Ph.D. Director, Scientific Review and Grants Administration American Association for Cancer Research SU2C Dream Teams at a Glance SU2C Dream Teams Grants ($6 Million -$22 Million; 3-4 years) Translational Multi-institutional (Large collaborating Teams) Near Term impact to patients First grants awarded in
2 Stand up to Cancer (SU2C) SU2C is a program of the Entertainment Industry Foundation created in 2008 to accelerate innovative cancer research that will get new therapies to patients quickly. SU2C is bringing together large teams of exceptional researchers and is encouraging collaboration rather than competition. By galvanizing the entertainment industry, SU2C creates awareness and builds broad public support for this effort. SU2C-Funded Research Grants (Leaders) (Partners) Funding # of Scientists # of Institutions Breast Cancer (Slamon Gray) $17,500, Epigenetics (Baylin/Jones) $10,220, PI3K (Cantley/Mills) $16,100, CTC Chip (Haber/Toner) $15,000, Pancreatic Cancer (Thompson Von Hoff Drebin) $22,000, Melanoma (Trent/LoRusso) (SU2C MRA) $6,000, Prostate (Chinnaiyan/Sawyers )(SU2C PCF) $10,000, Prostate (Small/Witte) (SU2C PCF) $10,000, Immunotherapy (Allison/Ribas) (SU2C CRI) $10,000, Pediatrics (Maris/Mackall) (SU2C St. Baldrick s) $14,500, SU2C KWF Dream Team $8,000,000 TOTALS $139,320,
3 Oregon Health & Science University Oregon Health & Science University Knight Cancer Institute California Institute of Technology (CalTech) Cancer Commons City of Hope Lawrence Berkeley National Laboratory Salk Institute for Biological Studies Sanford Burnham Medical Research Institute Scripps Translational Science Institute (STSI) Stanford University UCLA Jonsson Comprehensive Cancer Center UCSF Helen Diller Family Comprehensive Cancer Center University of California, Berkeley University of California, Davis University of California, Davis Cancer Center University of California, Los Angeles University of California, San Diego University of California, San Francisco University of California, Santa Cruz University of Southern California USC Norris Comprehensive Cancer Center University of British Columbia BC Cancer Agency The Vancouver Prostate Center Fred Hutchinson Cancer Research Center Seattle Children's Research Institute University of Washington Affiliated Institutions Comprehensive Cancer Centers of Nevada Lovelace Respiratory Research Institute Karmanos Cancer Institute (KCI) Michigan State University University of Michigan University of Michigan Comprehensive Cancer Center Wayne State University Mayo Clinic Rochester McMaster University University of Wisconsin Children's Hospital of Philadelphia Magee Women's Hospital Temple University Temple University, Fels Institute for Cancer Research and Molecular Biology University of Pennsylvania University of Pennsylvania Abramson Cancer Center University of Pittsburgh University of Pittsburgh Cancer Institute University of Pittsburgh Medical Center Indiana University Northwestern University The Hospital for Sick Children Boston Children's Hospital Brigham & Women's Hospital Dana Farber Cancer Institute Harvard Medical School Massachusetts General Hospital The Broad Institute Beth Israel Deaconess Medical Center Cold Spring Harbor Laboratory Columbia University Columbia University Herbert Irving Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Mount Sinai School of Medicine New York University Weill Cornell Medical College Princeton University University of Medicine & Dentistry of New Jersey Howard Hughes Medical Institute Johns Hopkins University Johns Hopkins University Kimmel Comprehensive Cancer Center National Cancer Institute Georgetown University, Lombardi Comprehensive Cancer Center Lineberger Comprehensive Cancer Center, University of North Carolina Map includes ONLY institutions represented by Dream Team Members currently working on SU2C funded research Mayo Clinic Scottsdale Biodesign Institute at Arizona State University Translational Genomics Research Institute (TGen) Baylor College of Medicine Baylor College of Medicine, Duncan Cancer Center Texas Children's Cancer Center Texas Oncology Baylor Charles A. Sammons Cancer Center University of Texas M.D. Anderson Cancer Center Mayo Clinic Florida 5 International Institutions Australia Queensland Institute for Medical Research The George Institute for Global Health Netherlands Erasmus Medical Center Netherlands Cancer Institute University Medical Center Utrecht Spain Centro Nacional de Investigaciones Oncológicas (CNIO) Vall d'hebron Institute of Oncology UK Institute of Cancer Research Royal Mardsen Hospital The Institute of Cancer Research Original 2009 SU2C Dream Teams An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their Resistance Phenotypes - Slamon-Gray Bioengineering and Clinical Applications of Circulating Tumor Cell Chip Haber/Toner Bringing Epigenetic Therapy to the Forefront of Cancer Management Baylin/Jones Cutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer - Thompson-Von Hoff- Drebin Targeting the PI3K Pathway in Women's Cancers Cantley/Mills 3
4 New Dream Teams Targeting Adaptive Pathways in Metastatic Treatment- Resistant Prostate Cancer (SU2C-PCF) Small/Witte Precision Therapy of Advanced Prostate Cancer (SU2C-PCF) Chinnaiyan/Sawyers Personalized Medicine for Patients With BRAF Wild- Type (BRAFwt) Cancer (SU2C-MRA) Trent/LoRusso Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy (SU2C-CRI) Allison-Ribas Immunogenomics to Create New Therapies for High- Risk Childhood Cancers (SU2C-St. Baldrick s) - Maris/Mackall SU2C Scientific Advisory Committee (SAC) Phillip A. Sharp, Ph.D., Chairperson Arnold J. Levine, Ph.D., Vice Chair William G. Nelson, M.D., Ph.D., Vice Chair Julian Adams, Ph.D. Angelika Amon, Ph.D. Kenneth C. Anderson, M.D., Ph.D. Frederick R. Appelbaum, M.D. Elizabeth H. Blackburn, Ph.D. Richard B. Gaynor, M.D. William N. Hait, M.D., Ph.D. Lee J. Helman, M.D. Waun Ki Hong, M.D. Carl H. June, M.D. William G. Kaelin Jr., M.D. Michael B. Kastan, M.D., Ph.D. Richard D. Kolodner, Ph.D. Guillermina (Gigi) Lozano, Ph.D. Thomas J. Lynch Jr., M.D. Tak W. Mak, Ph.D. Cecil B. Pickett, Ph.D. Nancy A. Roach Laura K. Shawver, Ph.D. Ellen V. Sigal, Ph.D. David A. Tuveson, M.D., Ph.D. 4
5 SU2C Dream Team Process Scope of the grant is determined by the SAC Press release announcement issued (Call for Ideas), marketing Receive LOIs (6 weeks) Teams develop ideas and submit full proposals (6 weeks) Teleconference to select top ideas for full proposal submission (3 4) SAC scores and critiques ideas on proposalcentral. In person selection meeting: Teams present their ideas, winning Team selected SU2C approval: EIF Board of Directors approval Awardees notified, press release issued Project starts Subcontracts between lead institution and other institutions Grant Agreement (contract) negotiated with lead institution SAC Review Team Constituted Submission of Progress Reports (every 6 months) Progress review visits (every 6 months) SU2C Model What is the definition of success? Number of publications? Number of patents? Number of clinical trials? Number of new drugs tested? Leverage funds? Scientific impact and patient benefit! 5
6 New York Times, Jan 22, 2013 New York Times, Sept 6,
7 2009 Dream Team Publications Dream Team Collaborations Pediatric CTC Prostate 1 Prostate 2 PI3K SU2C Data Portal Breast Immunology Pancreatic Epigenetic Melanoma 7
8 Mandatory Meetings SU2C Annual Summit SU2C DT leaders present their latest findings and are reviewed by the SAC Highly collaborative environment SU2C activities at the AACR Annual Meeting Dream Teams have in-person meetings Meetings with other Dream Team Leaders and SAC Presentations at open sessions Clinical Trials Summary 49 trials planned 41 trials currently active 13 trials completed 3,075 patients enrolled in SU2C clinical trials to date 8
9 Industry collaboration (28) Industry Partners # Epigenetics PI3K Breast Cancer CTC Chip Pancreatic Melanoma Prostate (1) Prostate (2) Immunology Pediatric Abbott 1 Amgen (incl. Dompe s.p.a.) 3 Aragon Pharmaceuticals 2 Astellas 1 Astex Pharmaceuticals 1 AstraZeneca 5 Bayer Pharmaceuticals 1 Biomarin 1 Bristol Myers Squibb 3 Celgene (incl. Abraxis Bioscience) 2 Eli Lilly & Company (incl. ImClone Systems) 2 Exelixis 2 GSK 5 Janssen 2 MedImmune 1 Medivation 1 Merck 2 Myriad Genetics 1 Novartis 5 OncoGenex Pharmaceuticals 2 OSI Pharmaceuticals 1 Pfizer 2 Plexxikon 1 ProGen 1 Roche (Genentech) 4 Sanofi Aventis 1 Syndax Pharmaceuticals 1 Takeda/Millenium Difficulties of Large Multi-Institutional Teams: Lessons learned Coordination of Research Projects-Collaboration. Because of the size of the Teams, coordinating research to maximize efficiency and scientific output can be challenging. Importance of dynamic leaders Frequent face-to-face meetings and teleconferences (mandatory) Project manager Delay in contract execution. This is often due to inconsistent communication between the Investigators and the Institutions contract administration staff during the contract negotiation phase. Frequent follow up from the AACR Deadline for contract execution Involvement from Leader (PIs) Inconsistencies in contract language. Some Institutions are state agencies that have very specific laws regarding liability insurance, indemnification, reporting period, etc. Have a standard subcontract, and try to insist on consistent language Keep track of differences and adapt process 9
10 Difficulties of Large Multi-Institutional Teams: Lessons learned Intellectual property. Currently, AACR/SU2C does not claim any rights to I.P., but multi-institutional agreements sometimes have different viewpoints on how the I.P. matters should be resolved. Involve PIs Communication. It is the Lead Institution s responsibility to inform AACR on all matters related to press releases, publishing of peer reviewed articles, or any other general press related to the Team, but is not done on a consistent basis. Provide PIs with clear information at the beginning of the grant regarding expectations (toolkit) Project Managers, PIOs Accuracy of Progress/Financial Reports. Challenges related to the Leader reviewing and approving financial reports and progress reports prior to submission to the AACR. Project Manager Constant interactions with Institution Financial/Grant Office Summary SU2C has provided, through the Dream Team concept, a new, innovative model for accelerating cancer research and for translating findings from bench to bedside in a short timeframe. Teams being evaluated based on conventional metrics as well as on cancer patient impact. Large teams have definite set of challenges, but most can be addressed with appropriate measures. 10
TEAM SCIENCE IN THE NEW ERA OF CANCER RESEARCH AND TRANSLATIONAL MEDICINE
TEAM SCIENCE IN THE NEW ERA OF CANCER RESEARCH AND TRANSLATIONAL MEDICINE Margaret Foti, PhD, MD (hc) Chief Executive Officer SWOG Meeting San Francisco, CA April 26-29, 2017 American Association for Cancer
More information8:30-9:00 Increased dependence on glutamine in PTEN-deficient breast cancer Ramon E. Parsons, Icahn School of Medicine at Mount Sinai, New York, NY
CONFERENCE PROGRAM SATURDAY, OCTOBER 7 3:00 p.m.-7:00 p.m. Salon 3 of the Terrace Welcome and Keynote Lectures 6:00 p.m.-7:30 p.m. Session Chair: Ramon E. Parsons, Icahn School of Medicine at Mount Sinai,
More information8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina
FIRST ANNOUNCEMENT 8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina The 8 th Conference of IAOC "Current
More informationKey ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
More informationAdvances in Breast Cancer Research: Genetics, Biology, and Clinical Applications
An AACR Special Conference on October 12-15, 2011 The Fairmont San Francisco San Francisco, CA Wednesday, October 12 7:00 p.m.-8:00 p.m. Opening Keynote Address Chairperson: Jeffrey M. Rosen, Baylor College
More informationMelanoma Research Alliance-Pfizer Academic-Industry Partnership Awards
Melanoma Research Alliance-Pfizer Academic-Industry Partnership Awards Wendy K.D. Selig, President & CEO, MRA Julia Perkins, M.D. Medical Director, Oncology, Pfizer Melanoma Research Alliance Mission:
More informationWelcome from the chairpersons Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA
Thursday, May 12, 2016 6:00 p.m.-7:30 p.m. Opening Plenary Session Welcome from the chairpersons Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA Opening remarks from the lead supporters
More informationConference Program. Genomic heterogeneity in localized lung cancer Andrew Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX
NOTE: Saturday, February 7 1:00 p.m.-3:00 p.m. Session A1: Cancer Genomics and Epigenomics Session Chairperson: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA Genomic heterogeneity in localized
More informationMayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium 2018
Mayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium 2018 October 26-27, 2018 Program Schedule Friday, October 26, 2018 7:30 a.m. Registration & Continental Breakfast 8:00 Welcome Announcements GLOBAL
More informationThe Heart Institute Tenth Anniversary Update. October 23, 2017
The Heart Institute Tenth Anniversary Update October 23, 2017 Organizational Structure Medicine Surgery Imaging Anesthesiology Pediatrics Basic Biomedical Sciences BEFORE AFTER * Services provided by contract
More informationOrganizational, or Other Financial Benefit None None None None None None. None None None None None None
Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor
More informationFebruary 9, The Vice President Old Executive Office Building Washington, DC Dear Mr. Vice President:
February 9, 2016 The Vice President Old Executive Office Building Washington, DC 20501 Dear Mr. Vice President: As the nation s leading organizations focused on promoting cancer research and prevention,
More informationPreventing BRCA-related cancer: A think tank for innovative strategies, milestone objectives and research priorities
BANBURY CENTER REPORTS Preventing BRCA-related cancer: A think tank for innovative strategies, milestone objectives and research priorities Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor,
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC) For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians
More information7:00 p.m.-7:15 p.m. Welcome Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
SUNDAY, DECEMBER 9 7:00 p.m.-8:00 p.m. WELCOME AND KEYNOTE ADDRESS 7:00 p.m.-7:15 p.m. Welcome Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 7:15 p.m.-8:00 p.m.
More informationFirst-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
Key ASCO Presentations Issue 7, 2010 First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) For more visit ResearchToPractice.com/5MJCMT2010
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationStaying on top of the current research landscape with InCites Benchmarking & Analytics: An immuno-oncology case study
Staying on top of the current research landscape with InCites Benchmarking & Analytics: An immuno-oncology case study SLA Annual Conference Biomedical & Life Sciences Division Breakfast June 2017 Amy Braden,
More informationThe National Cancer Institute Cancer Centers Program. The Cancer Centers Program of the National Cancer Institute (NCI) supports major
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The National Cancer Institute
More informationConference Program. All sessions will take place in the Regency Ballroom unless otherwise noted.
Conference Program All sessions will take place in the Regency Ballroom unless otherwise noted. Monday, June 18 7:30 p.m.-9:00 p.m. Keynote Presentations and Discussion: Pancreatic Cancer 2012 Do We Have
More informationImmunotherapy Approaches in Lymphoma
Immunotherapy Approaches in Lymphoma John Kuruvilla MD FRCPC 1 Disclosures for John Kuruvilla MD Research Support Employee Leukemia and Lymphoma Society US, Rasch Foundation Roche, N/A Consultant Abbvie,
More informationCourse Organizers: Neal Copeland, Ph.D., The Houston Methodist Research Institute Nancy Jenkins, Ph.D., The Houston Methodist Research Institute
Saturday, August 20 25 th ANNUAL SHORT COURSE ON EXPERIMENTAL MODELS OF HUMAN CANCER August 20-28, 2016 Course Organizers: Neal Copeland, Ph.D., The Houston Methodist Research Institute Nancy Jenkins,
More informationSWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology
SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology Lee M. Ellis, MD SWOG Vice Chair, Translational Medicine Departments of Surgical Oncology and
More informationTHE UC SANTA CRUZ GENOMICS INSTITUTE. David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director
THE UC SANTA CRUZ GENOMICS INSTITUTE David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director April 8, 2015 OUR MISSION Unlocking the world s genomic data to accelerate medical
More informationMayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium 2018
Mayo Clinic Pancreatic and Hepato-Biliary Cancer Symposium 2018 October 26-27, 2018 Program Schedule Friday, October 26, 2018 7:30 a.m. Registration & Continental Breakfast 8:00 Welcome Announcements Mitesh
More informationJOINT STATEMENT BY MEMBERS OF THE NATIONAL COMPREHENSIVE CANCER NETWORK PROSTATE CANCER GUIDELINES PANEL
JOINT STATEMENT BY MEMBERS OF THE NATIONAL COMPREHENSIVE CANCER NETWORK PROSTATE CANCER GUIDELINES PANEL We represent 23 of our nation s leading cancer hospitals on the National Comprehensive Cancer Network
More informationCall for Nominations. Opens: May 1, 2017 Deadline: September 30, 2017
2018 Call for Nominations Opens: May 1, 2017 Deadline: September 30, 2017 About the Szent-Györgyi Prize for Progress in Cancer Research The Szent-Györgyi Prize for Progress in Cancer Research was established
More informationVersion 3.0, March 2015
NACC Uniform Set Element Dictionary For the Milestones Form sion 3.0, March 2015 Copyright 2015 University of Washington. Created and published by the ADC Clinical Task Force (John C. Morris, MD, Chair)
More informationCancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023
Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023 Table of Contents Cancer Immunotherapy Artificial Intelligence: Executive Summary The study is designed
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationSession Chair: Lynette Denny, University of Cape Town, Cape Town, South Africa
WEDNESDAY, JANUARY 18 Concurrent Sessions 1-2 15:00-16:30 Cervical Cancer Ballroom East Session Chair: Lynette Denny, University of Cape Town, Cape Town, South Africa Progress in scaling up cervical cancer
More informationRVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
More informationCYPRESS U CRITICAL UPDATE
CYPRESS U CRITICAL UPDATE CASE STUDIES IN CANCER CARE MANAGEMENT John Van Dyke, Interlink Copyright INTERLINK Care Management, Inc. 2014 Presented by: John Van Dyke Chief Executive Officer INTERLINK COE
More informationDONNA BOWERS & ALAN MILLER
BAYLOR HEALTH CARE SYSTEM ONCOLOGY NETWORK NEWS UPDATE WITH YOUR BHCS ONCOLOGY ANCHORS DONNA BOWERS & ALAN MILLER 1 The Evolution of Cancer Care Slash, burn and poison era Precision Medicine Casting out
More informationPatients Driving Progress
Patients Driving Progress Ellen V Sigal, PhD WIN Symposium 2018 June 25, 2018 Paris, France Nothing to disclose The Evolution of Patient Advocacy The Agnew Clinic, Thomas Eakins (1899) Partial mastectomy
More informationMolecularly Targeted Therapies: Mechanisms of Resistance
An AACR Special Conference on Molecularly Targeted Therapies: Mechanisms of Resistance May 9-12, 2012 Westin San Diego San Diego, CA Wednesday, May 9 7:00 p.m.-8:00 p.m. Opening Keynote Session BRAF and
More informationJason Luke, MD, FACP Assistant Professor of Medicine University of Chicago, USA BRIEF INTRODUCTION
SPEAKERS BIOGRAPHY Jason Luke, MD, FACP Assistant Professor of Medicine University of Chicago, USA Jason Luke, MD, is an Assistant Professor of Medicine at University of Chicago where he specializes in
More informationSecond Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer Proceedings from a CME Satellite Symposium at the 30 th Annual San Antonio Breast Cancer Symposium
More informationOvarian Cancers: Evolving Paradigms in Research and Care Report Release Wednesday, March 2, 2016
Ovarian Cancers: Evolving Paradigms in Research and Care Report Release Wednesday, March 2, 2016 Committee Membership Jerome F. Strauss, III, (Chair), Virginia Commonwealth University School of Medicine
More informationAssociation of Northern California Oncologists Annual Report
Association of Northern California Oncologists 2010 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
More informationAdvanced Epigenetic Technology BIO-Europe Spring 2018 Amsterdam, The Netherlands
Advanced Epigenetic Technology BIO-Europe Spring 2018 Amsterdam, The Netherlands March 13 th Zenith Profile Founded Company Status Products and Technology Location Financing 2014-2016 Shares Outstanding
More information23 rd Annual Cancer Progress Conference
23 rd Annual Cancer Progress Conference March 6 & 7, 2012 The Westin New York at Times Square AGENDA Tuesday, March 6, 2012 7:00am Continental Breakfast and Registration- Majestic Foyer 8:15-8:45am Opening
More informationStudy of Triple-Negative Breast Cancer is Most Cited in AACR Journal
MEDIA CONTACT: Craig Civale Craig.Civale@BaylorHealth.edu (817)709-7067 Study of Triple-Negative Breast Cancer is Most Cited in AACR Journal TGen, Baylor, US Oncology study revealed therapeutic drug targets
More informationAGENDA: FEBRUARY 22, 2018 INTRODUCTION
FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop with support from Cancer Research UK Combinations Alliance February 22-23, 2018 Bethesda, MD Purpose: There is great interest
More informationALBERTA PRINCIPAL INVESTIGATORS
ALBERTA PRINCIPAL INVESTIGATORS Dr. Gregory Cairncross is Head of the Department of Clinical Neurosciences at the University of Calgary and holder of the Alberta Cancer Foundation Chair in Brain Tumor
More informationInvited Journal: Nature Medicine. Sponsors: Thermo Fisher Novocure Merck. Venue: Spanish National Cancer Research Centre CNIO Auditorium Madrid, Spain
CNIO Frontiers Meetings Primary and Secondary Brain Tumors 19th-22nd February 2017 Organisers: Richard Gilbertson CRUK Cambridge Institute, UK Michael Weller University Hospital Zurich, Switzerland Massimo
More information6:00 p.m.-6:10 p.m. Welcome from Cochairs Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA
CONFERENCE PROGRAM FRIDAY, SEPTEMBER 21 3:00 p.m.-7:00 p.m. REGISTRATION 6:00 p.m.-8:10 p.m. WELCOME AND KEYNOTE LECTURES Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MA
More information2014 OREGON STATE FOOTBALL MEDIA GUIDE ALL-TIME SERIES RECORDS ALL-TIME SERIES RECORDS OVERTIME HISTORY. #GoBeavs
ALL-TIME SERIES RECORDS 2014 OREGON STATE FOOTBALL MEDIA GUIDE ALL-TIME SERIES RECORDS OPPONENT TOTAL H A N LAST Akron......................... 1-0 1-0 0-0 0-0 1987 Albany Athletic Club.......... 1-0 1-0
More informationCritical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
More informationFaculty. Course Directors. Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist
Faculty Course Directors Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist Non-financial Disclosure: Developer of Swallow RehApp Joseph Califano, MD UC San Diego Health
More informationThe Challenge of Accelerating Medical Solutions Through Philanthropy. Steve Case, Case Foundation Mike Milken, FasterCures
The Challenge of Accelerating Medical Solutions Through Philanthropy Steve Case, Case Foundation Mike Milken, FasterCures U.S. BABY BOOMERS Sources: MetLife Mature Market Institute Analysis U.S. Census
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationEmerging Data on the Role of Wnt Biology in Cancer
MEETING AGENDA Emerging Data on the Role of Wnt Biology in Cancer The Banbury Center, Cold Spring Harbor Laboratory, New York, USA October 7-10, 2018 This meeting was funded by Leap Therapeutics Lead Organizers:
More informationConference Co-Chairpersons
An AACR Special Conference Tumor Immunology and Immunotherapy: A New Chapter Presented in conjunction with the Cancer Immunology Working Group of the AACR December 1-4, 2014 Disney s Contemporary Resort
More informationWhat is the Situation Regarding Low Dose and Low Dose-Rate Ionizing Radiation in the USA? William F. Morgan, Ph.D., D.Sc
What is the Situation Regarding Low Dose and Low Dose-Rate Ionizing Radiation in the USA? William F. Morgan, Ph.D., D.Sc Biological Sciences Division Pacific Northwest National Laboratory USA wfmorgan@pnnl.gov
More informationOncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
More informationKey ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual
More information10th International Symposium on Translational Research in Oncology
You are cordially invited to the 10th International Symposium on Translational Research in Oncology Meeting Chairs: Prof John Crown (Dublin) Prof Robert Kerbel (Toronto) Attendance is free but registration
More information6:00 p.m.-8:00 p.m. OPENING KEYNOTE ADDRESSES AND SPECIAL LECTURE Salons EF
Sunday, October 1 6:00 p.m.-8:00 p.m. OPENING KEYNOTE ADDRESSES AND SPECIAL LECTURE 6:00 p.m.-6:45 p.m. Principles of response and resistance to immunotherapy Levi A. Garraway, Eli Lilly and Company, Indianapolis,
More informationFinding the Positives in Triple-Negative Breast Cancer:
Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11,
More informationTransatlantic Dream Team of Top Researchers Selected To Tackle One of Cancer s Deadliest Forms: Pancreatic Cancer
Transatlantic Dream Team of Top Researchers Selected To Tackle One of Cancer s Deadliest Forms: Pancreatic Cancer Stand Up To Cancer, Cancer Research UK, and The Lustgarten Foundation Fund Team with $12
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationASPO 2018 Roosevelt Hotel, New York, NY
ASPO 2018 Roosevelt Hotel, New York, NY SATURDAY, MARCH 10, 2018 Noon 3:00pm 3:00pm 7:00pm Mock Study Section (limited to 20 participants) Cancer Prevention & Control Associate Directors/Program Leaders
More informationPresenter Disclosure Information
Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444 Lawrence Fong, John Powderly II, Jason
More informationCAR T Cell Therapies Workshop
CAR T Cell Therapies Workshop May 15, 2018 Hilton Chicago Continental B Chicago Table of Contents CAR T Cell Therapies Workshop Supporters... p 2 Committee Listing... p 3 Faculty Listing... p 3 Faculty
More informationRanking Minority Member Senate Committee on Armed Services Senate Committee on Armed Services Washington, DC Washington, DC 20510
The Honorable John McCain The Honorable Jack Reed United States Senator United States Senator Chair Ranking Minority Member Senate Committee on Armed Services Senate Committee on Armed Services Washington,
More informationTargeted Agent and Profiling Utilization Registry
Targeted Agent and Profiling Utilization Registry Richard L. Schilsky, MD, FACP, FASCO Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Disclosure Information Richard
More informationEmerging Issues in Food and Drug Law: Implementation of FDASIA Innovative Drug Approvals: Breakthrough Therapies Arnold & Porter LLP, Washington DC
Emerging Issues in Food and Drug Law: Implementation of FDASIA Innovative Drug Approvals: Breakthrough Therapies Arnold & Porter LLP, Washington DC Ryan M. Hohman, JD, MPA Managing Director, Friends of
More informationESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
More information8:30 a.m.-10:00 a.m. PLENARY SESSION 1: BIOLOGY OF THE PI3K/MTOR PATHWAY Harbor Ballroom II and III
FRIDAY, NOVEMBER 30 6:00 p.m.-7:00 p.m. OPENING KEYNOTE SESSION Welcome remarks and keynote introduction Lewis C. Cantley, Cornell Medical College, New York-Presbyterian Hospital, New York, NY PI3Kinase
More informationEducational Forum on Lymphoma
NINETEENTH ANNUAL NORTH AMERICAN Educational Forum on Lymphoma October 24-26, 2014 Manhattan Beach, California THE PREMIER EDUCATION AND NETWORKING FORUM FOR PEOPLE WITH LYMPHOMA AND THEIR LOVED ONES n
More informationMelanoma. Research Alliance. Fast-Forwarding a Cure for Deadly Skin Cancer
. Melanoma Research Alliance Fast-Forwarding a Cure for Deadly Skin Cancer Vision Targeting an urgent problem. Melanoma often starts out small, misleadingly insignificant a change in a mole, a mark on
More informationPhase II Study of Clofarabine for Older Patients with Treatment-Naïve AML
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately
More informationImmediate Past President National Medical Association
Improved Survival but Continued Disparities in Cancer: The 1971 National Cancer Act through Moonshot 2017 Edith Peterson Mitchell, MD, FACP, FCPP Clinical Professor of Medicine and Medical Oncology Department
More informationNo Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
More informationImmunology and Immunotherapy 101 for the non-immunologist
Immunology and Immunotherapy 101 for the non-immunologist SITC Advances in Immunotherapy Seattle, WA 2016 Laura QM Chow Associate Professor University of Washington Associate Professor, Fred Hutchison
More informationKey ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
More informationKey ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationCCO Annual Report (2016) Editorial Office
CCO Annual Report (2016) Editorial Office editor@thecco.net Outline of the Report 1.Basic Information 2.Message from the Editors-in-Chief 3.Distribution of Editorial Board Members 4.Number of Published
More informationClinical Decision Support Technologies for Oncologic Imaging
Clinical Decision Support Technologies for Oncologic Imaging Ramin Khorasani, MD, MPH Professor of Radiology Harvard Medical School Distinguished Chair, Medical Informatics Vice Chair, Department of Radiology
More informationPROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund
PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund December 2018 EXECUTIVE SUMMARY As a top-ranked pediatric cancer center, Dana-Farber Cancer Institute combines first-rate patient care with groundbreaking
More informationLIVESTRONG Patient Navigation Services Program (PNSP)
Lance Armstrong Foundation LIVESTRONG Patient Navigation Services Program (PNSP) Caroline Huffman, LCSW, M.Ed. Navigation Landscape Patient Navigation Center at Ralph Lauren Center Dr Freeman s model American
More informationPeter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective
第 53 回日本癌治療学会学術集会 ASCO, ESMO, ECCO からの招聘演者と講演予定 Peter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective Ralf A. Stahel (President
More information24th Annual Prostate Cancer Foundation Scientific Retreat
24th Annual Prostate Cancer Foundation Scientific Retreat October 5-7, 2017 Omni Shoreham Hotel Washington D.C. 1 AGENDA Thursday, October 5, 2017 GENERAL SESSIONS Location: Regency Ballroom 8:00 AM Registration
More informationDay One Wednesday July 19, 2017
Day One Wednesday July 19, 2017 08.00 Registration & Coffee 09.00 Chair s Opening Remarks - Room: Huntington I/II Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research Laboratories
More information11th AACR JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision Medicine
11th AACR JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision Medicine Friday, Feb. 8 Saturday, Feb. 9 Sunday, Feb. 10 Monday, Feb. 11 Tuesday, Feb. 12 18:30 20:00 Welcome and
More informationCancer Center Support Grant
Cancer Center Support Grant Erin Bank, PhD Associate Director for Programs and Planning UCSF HDFCCC 03.14.2017 HDFCCC Staff Engagement Talk NCI Cancer Centers 1937: NCI established by Roosevelt Annual
More informationNew Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
More informationVolunteering in Oklahoma City, OK
6/17/2010 Oklahoma City Profile - Volunteering in information on volunteering and civic engagement Volunteering in Oklahoma City, OK Statistics for this area were collected within the Oklahoma City Metropolitan
More informationLife Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop
Life Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop Gregory A. Curt, MD, Chair U.S. Medical Science Lead, Emerging Products AstraZeneca -Oncology CEO Roundtable-I May
More informationMadrid March Manuel Hidalgo. Alberto Bardelli. Lillian Siu. Josep Tabernero. Application deadline February 23 rd
Spanish National Cancer Research Centre CNIO Frontiers Meetings 2015 Madrid 22 25 March 2015 New Trends in Anticancer Drug Development Application deadline February 23 rd Organisers Manuel Hidalgo Alberto
More informationMETASTATIC BREAST CANCER
Click Here to View at: www.iqanda-mbc.com The iq&a interactive Medical Intelligence Zone for METASTATIC BREAST CANCER Focus on Evidence-Based Treatment for Survival Prolongation Based on Receptor Status,
More informationMarch 14, The Food and Drug Administration (FDA) is facing a serious crisis that has significant implications for the nation s health.
March 14, 2007 An Open Letter to: Chairman Edward Kennedy and Senator Mike Enzi, Chairman John Dingell and Representative Joe Barton Members of the Senate Health, Education, Labor and Pensions Committee
More informationThe U.S. Preventive Services Task Force (USPSTF) makes
Annals of Internal Medicine Clinical Guideline Screening for Testicular Cancer: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement U.S. Preventive Services Task Force* Description:
More information2014 Coffey - Holden Prostate Cancer Academy Meeting
2014 Coffey - Holden Prostate Cancer Academy Meeting Beyond immune checkpoint blockade: New Approaches to targeting Host Tumor Interactions in Prostate Cancer June 26-29, 2014 Estancia Hotel La Jolla,
More information